Correlation of Tumor Marker Cancer Antigen (CA-125) against Hemoglobin, Leucocytes, and Platelet Lymphocyte Ratio in Ovarian Cancer Patients at RSUD ULIN Banjarmasin

Hermin Sabarudin

Abstract


CA-125 is the most commonly used tumor marker in ovarian cancer, its known as the "Gold Standard" for the diagnosis of ovarian cancer. CA-125 allegely related to the inflammatory mechanisms which associated with leukocytes and lymphocytes, as well as Lymphocyte Platelet Ratio. This study is to prove above hypothesis. The objective is to investigate CA-125 correlation as tumor marker of inflammatory hematology examination which consisting of Hemoglobin, leucocytes and PLR as indicator of inflammatory examination in ovarian cancer patient. The method is an observational analytic study with cross sectional retrospective descriptive. The sample is 42 patients medical record who are treated in Oncology Polyclinic RSUD ULIN in October 2014 - October 2017 period. Samples selected by time limitation method. Sampling technique using nonpropability method followed by purposive sampling method. After the data is taken and selected then processed into SPSS for normality test and continued by multiple linear regression test. The results showed that correlation analysis of CA-125 tumor marker on Hb, leukocyte and PLR levels was P = 858b; P value <0.05. The CA-125 relationship to Hb, leucocytes and PLR is a negative relationship (r Hb = -3,463, r leukocytes = -6,117, r PLR = -2.281), which means that more high the Hb, leukocyte and PLR value, conversely CA125 value become more low. The conclusions of this study is there no correlation of CA125 tumor marker against Hb, leucocytes and PLR in ovarian cancer patients. The results of this study indicate that the increasing of CA125 value is negative correlation because it is not followed by decreasing of Hb, increasing of leukocyte and PLR.

 


Keywords


Keywords : CA-125,Haemoglobin, leucocytes and PLR

Full Text:

PDF

References


Ordovician, O., Sima, C.S., Iansonos, A., Bell-McGuinn, K., Sabbatini, P.J., Leitao, M.M., et al. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patient with FIGO stage IIIC ovarian cancer. Gynecologic Oncology 115, 2009: 209-214.

Fauzan, R. Gambaran faktor risiko penggunaan kontrasepsi terhadap angka kejadian kanker ovarium di RSUPN Dr. Cipto Mangunkusumo Jakarta berdasarkan pemeiksaan histopatologik. (Tesis). Jakarta : Universitas Indonesia, 2009.

Clarke-Pearson, D.L. Screening for Ovarian Cancer. N Engl J Med, 2009: 361;2.

Yurkovetsky, Z., Skates, S., Lomakin, A., Nolen, B., Pulsipher, T., Modugno, F., et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol, 2010: 28:2159-2166.

Agarwal, P. and Kehoe, S. Serum tumour marker in gynaecological cancers. Maturitas 67, 2010: 46-53.

Gupta, D. and Lis, C.G. Role of CA-125 in predicting ovarian cancer survival – a review of the epidemiological literature. Journal of OvarianResearch, 2009, 2:13.

Lin WW and Karin M, 2007.A Cytokine-Mediated Link Between Innate Immunity, Inflamasi, and Cancer.Department of Pharmacolgy, College of Medicine, National Taiwan Universty, Taipe, Republic of China: 1175-1183.

Kemenkes RI. 2011. Pedoman Interpretasi Data Klinik. Jakarta :Direktorat Jenderal Bina Kefarmasian Dan Alat Kesehatan.

Raungkaemaniee S, et al. Platelet to lymphocyte Ratio as a prognostic factor for ephithelial ovarian cancer. J Gynec oncol 2012;23:4:265-273

Budiana, I Nyomana. Peran Klinis CA125 pada kanker ovarium. Bagian obstetri dan Ginekologi Fakultas Kedokteran Universitas Udayana. Bali : 2014

Tuxen MK, et al. Serum tumour Marker CA125in monitoring of ovarian cancer during first-line chemotheraphy.British Journal of Cancer, 2001:84:10, 1301–1307.

Ekasanti, Riesti, dkk. Platelet limfosit ratio (PLR) pada kanker ovarium. Jurnal kedokteran dan kesehatan Wadi Husada Vo.1 No.2, April-Juni 2014.

Karst, A.M. and Drapkin, R. Ovarian Cancer Pathogenesis: A Model In Evolution. Journal of Oncology, 2010: Article ID 932371.

Boivin, M., Lane, D., Piche, A., Rancourt, C. CA125 (MUC16) Tumor Antigen Selectively Modulates The Sensitivity of Ovarian Cancer Cells to Genotoxic Drug-induced apoptosis. Gynecologic Oncology 115, 2009: 407-413.

Rarung, M. Sensitifitas dan Spesifisitas Petanda Tumor CA125 Sebagai Prediksi Keganasan ovarium. JKM Vol.8 No.1, Juli 2008: 9-14.

Jordan, S.M., and Bristow, R.E. Ovarian Cancer Biomarkers As Diagnostic Triage Test. Current Biomarker Findings 2013:3 35-42.

Bambace NM, Holmes CE. The Platelets Contribution to cancer progression. Journal of Thrombosis and Hemowstasis. 2011;9:237-49

Crasta JA,et al. Significance Of Preoperative Tromboscytosis In Epithelial Ovarian Cancer. Indian Journal pathology and Microbiology. 2010;53:1:54-5.

Berek, J. Epithelial ovarian cancer: Piver editor. Handbook of gynecologiconcology. 2nd edition. Lipponcott Williams&wilkins, 2005: p586.

Schorge, J.O. et al. Williams Gynecology. Mc Graw Hill, 2008: p716.




DOI: http://dx.doi.org/10.30742/jikw.v7i1.328

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Hermin Sabarudin

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

garuda

Jurnal Ilmiah Kedokteran Wijaya Kusuma 

ISSN: 1978-2071(print); 2580-5967 (online)
 
Published by the Institute for Research and Community Services (LPPM) of University of Wijaya Kusuma Surabaya.
Surabaya, Indonesia
 
Creative Commons License
All publications by Jurnal Ilmiah Kedokteran Wijaya Kusuma are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
 
web
counter View My Stats